Bronchodilating test in patients with chronic obstructive pulmonary disease
Abstract
Our aim was to investigate an effect of salbutamol on bronchial obstruction, lung hyperinflation and clinical signs in patients with severe chronic obstructive pulmonary disease (COPD).
Thirty three COPD patients (the average age was 58±2 yrs, FEV1 was 27.2±1.9%, FEV1/FVC was 33.7±1.6%) were examined using spirometry, body plethysmography; the breathlessness intensity was evaluated with a visual analogue scale (VAS), the exertion tolerance was assessed by 6-min walk test (6MWT) before and 15-20 min after inhalation of salbutamol.
There was a significant increase both in FVC and FEV1 (10±2% and 4±1%, p<0.0001) after 200 meg of salbutamol but FEV1/FVC ratio decreased by 0.6%. Salbutamol caused the reliable growth of lung volume values (VC, RV, FRC and IC changed by 9±1%, -18±3%, -9±1% and 9±1%, p<0.0001 for each). TLC did not change significantly (8.45±0.25 and 8.41 ±0.26 L). There was a considerable reduction in the breathlessness severity as measured by the VAS score (4.9±0.4 to 3.9±0.3, p<0.0004) and an increase in the exertion endurance (from 63% pred. to 66% pred., p<0.0065). Correlations were found between the clinical signs severity and the lung hyperinflation. Our data demonstrated that salbutamol caused a significant reduction in FRC and an increase in IC notwithstanding the absence of FEV1, dynamics in majority of the COPD patients. The lung hyperinflation dynamics resulted in the breathlessness relief and the improvement of the exertion tolerance.
About the Authors
A. V. Cherniak
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
S. N. Avdeev
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
T. L. Pashkova
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
Z. R. Aisanov
НИИ пульмонологии Минздрава РФ
Russian Federation
Russian Federation
References
1. Авдеев С.Н., Чучалин А.Г. Дыхательная недостаточность при хронической обструктивной болезни легких. В кн.: А.Г. Чучалин (ред.) Хронические обструктивные болезни легких. М.: ЗАО Изд-во Бином; СПб: Невский диалект; 1998. 249-275.
2. Айсанов З.Р., Кокосов А.Н., Овчаренко С.И. и др. Хронические обструктивные болезни легких. Федеральная программа. Рус. мед. журн. 2001; 9 (1): 9-34.
3. Гриппи М.А. Патофизиология легких. М.: ЗАО Изд-во "Бином"; СПб: Невский диалект; 1999.
4. Мухорлямов Ю.И., Агранович А.И. Органы дыхания. В кн.: Кассирский И.А. (ред.) Справочник по функциональной диагностике. М.: Изд-во "Медицина"; 1970. 244-283.
5. American Thoracic Society. 1987. Standardization of spirometry — 1987 update. Am. Rev. Respir. Dis. 1987; 136 (5): 1285-1298.
6. Belman M.J., Botnick W.C., Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during y exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967-975.
7. Enright P.L., Sherrill D.L. Reference equations for the sixminute walk in healthy adults. Ibid. 1998; 158 (5, Pt 1): 1384-1387.
8. Filuk R.B., Easton P.A., Anthonisen N.R. Response to large dose of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1985; 132: 871-874.
9. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop report. - NIH Publication 2701, April 2001. 1-100.
10. Guyatt G.H., Sullivan M.J., Thompson P.J. The 6-min walk: a new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 1985; 132: 919-923.
11. Guyatt G.H., Townsend M., Pugsley S.O. Bronchodilators in chronic air-flow limitation effects on airway function exercise capacity and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.
12. Hyatt R.E. The interrelationship of pressure flow and volume during various respiratory maneuvres in normal and emphysematous patients. Ibid. 1961; 83: 676-683.
13. Koulouns N.G., Valta P., Lavoie A. A simple method to detect expiratory flow limitation during spontaneous breathing. Eur. Respir. J. 1995; 306-313.
14. Nisar М., Hams J.E., Pearson M.G., Calverley P.M.A. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 555-559.
15. O'Donnell D.E., Lam М., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.
16. O'Donnell D.E. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117: 42-47.
17. O'Donnell D.E., Forkert L., Webb K.A. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur. Respir. J. 2001; 18: 914-920.
18. Quanjer Ph. H., Tammelin G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party "Standardization of Lung Function Tests". European Coal and Steel Community. Ibid. 1993; 6 (suppl. 16): 5-40.
19. Tantucci C., Duguet A., Similowski T. et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Ibid. 1998; 12: 799-804.
Review
For citations:
Cherniak A.V., Avdeev S.N., Pashkova T.L., Aisanov Z.R. Bronchodilating test in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2003;(1):51-56. (In Russ.)
Views:
2150
Email this article 